Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...
Significant improvement of 18 points in Unified Parkinson’s Disease Rating Scale (UPDRS) Part 3 in the high dose group at 26 weeks Significant improvement in the Parkinson’s Disease Questionnaire (PDQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results